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A rapid, sensitive, and accurate high performance liquid chromatography for the determination of axitinibe 
(AN) in rabbit plasma is developed using crizotinibe as an internal standard (IS). Axitinibe is a tyrosine 
kinase inhibitor, used in the treatment of advanced kidney cancer, which works by slowing or stopping 
the growth of cancer cells. The chromatographic separation was performed on a Waters 2695, Kromosil 
(150 mm × 4.6 mm, 5 µm) column using a mobile phase containing buffer (pH 4.6) and acetonitrile in 
the ratio of 65:35 v/v with a flow rate of1 mL/min. The analyte and internal standard were extracted using 
liquid-liquid extraction with acetonitrile. The elution was detected by photo diode array detector at 320 
nm.The total chromatographic runtime is 10.0 min with a retention time for axitinibe and IS of 5.685, 
and 3.606 min, respectively. The method was validated over a dynamic linear range of 0.002-0.2µg/mL 
for axitinibe with a correlation coefficient of r2 0.999. 
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INTRODUCTION
Axitinibe is an oral, potent, and selective inhibitor 
of vascular endothelial growth factor receptors (VEGFR) 
1, 2, and 3 (Cohenet al., 2008). Axitinibe is marketed 
under the name Inlyta (2014), and if one previous systemic 
therapy for kidney cell cancer has failed, axitinibe is 
indicated (leaflet (Pfizer) revised 8/2014). IUPAC name 
was (N-methyl-2-[[3-[(E)-2-pyridin-2-yl-ethenyl]-1H-
indazol-6-yl]sulfanyl]benzamide). It is soluble in DMSO 
(42 mg/mL at 25°C), water (<1 mg/mL at 25 °C), ethanol 
(<1 mg/mL at 25 °C), methanol, and DMF (~0.25 mg/mL) 
(NCBI Compound Database, 2016). Axitinibe prevents 
the progression of cancer by inhibiting angiogenesis and 
blocking tumor growth (Van Geel, Beijnen, Shellens et 
al., 2012). The chemical structure of axitinibe is given in 
Figure1.
Crizotinibe is a tyrosine kinase receptor inhibitor 
(Wani et al.,2014). More specifically, it inhibits anaplastic 
lymphoma kinase (ALK), hepatocyte growth factor 
receptor (HGFR, c-MET), and Recepteur d’Origine 
Nantais (RON). Abnormalities in the ALK gene caused 
by mutations or translocations may lead to the expression 
of oncogenic fusion proteins. In patients with NSCLC, 
they have the EML4-ALK gene. Crizotinibe inhibits ALK 
tyrosine kinase, which ultimately results in the decreased 
proliferation of cells that carry the genetic mutation and 
tumor survivability (Wani et al., 2014; Probhash et al., 
2013).
The literature survey revealed very few analytical 
methods for the estimation of axitinibe (Sagar, Bera, 
Panda et al., 2016; Sarada, Reddy, 2016), which included 
estimation in biological fluids (Garrettet al., 2014). The 
available methods include LC-MS (Sparidans et al., 2009) 
ion mobility spectrometry and DART mass spectrometry 
FIGURE 1 - Structure of axitinibe.
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(Likar et al., 2011). The present work emphasizes the 
development of a rapid, economical and simple method, 
which utilizes protein precipitation for sample preparation 
and HPLC using UV detection for the quantification of 
axitinibe in rabbit plasma. 
EXPERIMENTAL
Chemicals and reagents
The pure samples of axitinibe and crizotinibe were 
obtained from Sigma-Aldrich. HPLC grade Acetonitrile, 
HPLC grade Methanol and all other chemicals were 
obtained from Merck chemical division, Mumbai. HPLC 
grade water obtained from a Milli-Q water purification 
system was used throughout the study. Rabbit plasma was 
purchased from albino labs, Miyapur, Hyderabad.
Instrumentation
Chromatography was performed with the waters 
2695 HPLC system provided with a high speed 
autosampler, column oven, degasser and 2996 PDA 
detector to provide a compact process and with class 
Empower-2 software.
Chromatographic method
The separation was carried on a Kromosil C18 
analytical column (150 mm×4.6 mm×5 µm) using the 
mobile phase containing buffer and acetonitrile in the 
ratio of 65:35%v/v; this was delivered isocratically at 
a flow rate of 1 mL/min. The injection volume was 10 
µL and the run time was 10 min. The temperatures of 
the column and autosampler were maintained at 30 °C 
and 5 °C, respectively. The detection was performed at a 
wavelength of 320 nm.
Buffer preparation 
One mL of perchloric acid was transferred into a 
1000 mL volumetric flask and made up to 1000 mL with 
water; pH was adjusted to 4.6 using triethylamine.
Preparation of standard solutions
The standard stock solution of axitinibe was 
prepared at 0.1mg/mL with the diluent composition of 
water:acetonitrile 50:50%v/v. Axitinibe spiking solutions 
(0.46 µg/mL to 46 µg/mL) were prepared from stock 
solution. Calibration standards were prepared by spiking 
stock solution into blank plasma to obtain 0.002, 0.004, 
0.02, 0.04, 0.08, 0.1, 0.15 and 0.2 µg/mL.
Sample preparation
To 250 µLof drug free plasma, 50 µL of internal 
standard and 10 µL of axitinibe was spiked and 2 mL of 
acetonitrile was added. The above mixture was subjected 
to the cyclomixer for 15 s, vortexed for 2 min and finally 
centrifuged for 3 min at 3200 rpm. After centrifugation, 
the organic layer was collected and 10 µL was directly 
injected into HPLC.
Method validation
A thorough and complete method of validation 
was performed following the USFDA guidelines. The 
method was validated for system suitability, autosampler 
carryover, specificity and screening of the biological 
matrix, sensitivity, matrix effect, linearity, precision 
and accuracy, recovery of analyte and internal standard, 
ruggedness on precision accuracy and linearity (Maring et 
al., 2005; Rote et al., 2013; Phatak, Vaidya, Phatak, 2014), 
reinjection reproducibility and stability on day zero, long 
batch, LT at -28 °C and LT at -80 °C.
System suitability was assessed by a middle 
quality control (MQC) sample at a concentration of 
0.08 µg/mL, with six homogenous injections; relative 
standard deviation (%RSD) values for retention time 
and response of the analyte and internal standard were 
calculated. Autosample carryover was assessed by 
injecting a sequence of standard blank, an upper limit of 
quantification (ULOQ) concentration of 0.2 µg/mL and 
a lower limit of quantification (LLOQ) concentration of 
0.002 µg/mL.
Specificity and screening of the biological matrix 
was assessed using six blank standards and LLOQ level 
samples. All samples were checked for any interference 
of blank and sample response. Sensitivity was assessed 
by LLOQ level sample to determine the lowest limit of 
detection and the % mean accuracy and % CV (coefficient 
of variation) were calculated. Matrix effect on analyte 
quantitation with respect to consistency in signal 
(suppression/enhancement) was checked in six different 
lots of axitinibe plasma; three replicates, at LQC and HQC 
levels, were prepared from these plasma samples (total 36 
QC samples) and assessed for accuracy in terms of % bias 
in all of the QC samples.
Linearity of the method was determined by analysis 
of standard plots associated with an 8-point standard 
calibration curve. The calibration curve was found be 
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linear over the range of 0.002–0.2 µg/mL. Intra-batch 
and inter-batch accuracy and precision were evaluated at 
four different concentrations levels (LLOQ, LQC, MQC 
and HQC) in six replicates for both analytes. Mean values 
were obtained for calculated drug concentrations over 
these batches. The accuracy and precision were calculated 
and expressed in terms of % accuracy and coefficient of 
variation (% CV), respectively.
Recovery of the analytes from the extraction 
procedure was performed at LQC, MQC, and HQC 
levels. It was evaluated by comparing the peak area of 
the extracted samples (spiked before extraction) to the 
peak area of unextracted samples (quality control working 
solutions spiked in extracted plasma). Ruggedness of 
the method was assessed by using different analysts for 
linearity, precision and accuracy in the levels of ULOQ, 
LQC, MQC and HQC. 
Stability studies were performed at Zero hours, Long 
batch, LT at -28 °C and LT at -80 °C. Day zero had two 
samples with six replicates of HQC and LQC levels. Long 
batch had 35 replicates of LLOQ, LQC, MQC and HQC 
level of samples with %Mean accuracy. LT at -28 °C and 
LT at -80 °C had HQC and LQC levels with % stability 
findings by comparing stability sample with freshly spiked 
samples.
RESULTS AND DISCUSSIONS
The chromatographic separation of axitinibe using 
crizotinibe was optimized after several trials using the C18 
column mobile phase with different ratios of perchloric 
acid buffer and acetonitrile at various pH. The best results 
were achieved by using perchloric acid buffer (pH 4.6 
adjusted by using triethyl amine) and acetonitrile in the 
ratio of 65:35v/v. Good sensitivity was obtained at a 
wavelength of 320 nm. The best separation was achieved 
with a flow rate of 1 mL/min. The analyte and internal 
standard were eluted at 5.685, and 3.606 min, respectively.
 
System suitability and auto sampler carryover
Six replicate samples of middle quality control 
samples at different concentrations were injected along 
with internal standards and % CV was calculated. The 
% CV of the retention time of analyte and IS was found 
to be ≤2.00%. The % CV of the peak area ratio of 
analyte to IS was found to be ≤5.00%. The results were 
found to be within the limits and are summarized in 
Table I.
The carryover experiment was performed to ensure 
that it does not affect the accuracy and precision. There 
was no carryover observed. The results were presented 
in Table II.
Specificity and screening of biological matrix
The response of interfering peaks in the standard 
blank at the retention time of analyte should be ≤20.00% 
of that in LLOQ. The response of interfering peaks in 
the standard blank at the retention time of IS should be 
≤5.00% of that in LLOQ. All of the samples were found 
to be free of interference at retention time of the analyte 
in blank samples. The results are shown in Table III. This 
shows the specificity of the method towards axitinibe by 
the absence of interfering peaks.
Sensitivity
The accuracy and precision of axitinibe at LLOQ 
level was found to be 6.50% CV and % mean accuracy 
was found to be 107.31%. Acceptance criteria state that at 
TABLE I - System suitability data
Sample Name
Analyte IS 
Area Ratio
Area Rt (min) Area Rt (min)
MQC 24515 5.63 26987 3.61 0.9084
24698 5.63 27012 3.61 0.9143
25156 5.68 26358 3.62 0.9544
24956 5.63 27114 3.62 0.9204
24658 5.62 26874 3.62 0.9175
25012 5.63 26914 3.61 0.9293
MEAN  5.635  3.615 0.92407
SD 0.0200 0.0059 0.016394
%CV 0.35 0.16 1.77
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least 67% (4 out of 6) of samples should be within 80.00-
120.00%. % Mean accuracy should be within the range 
80.00-120.00%. % CV accuracy should be ≤20.00%. The 
results meet the acceptance limit and are shown in Table 
IV. This confirms that the method is highly sensitive for 
axitinibe.
Matrix effect
The matrix effect data of HQC and LQC are 
presented in Table V. The acceptance criteria state that at 
least 67% (2 out of 3) of samples at each level should be 
within the range 85.00-115.00%. At least 80% (5 out of 6) 
of the matrix lot should be within the acceptance criteria. 
The % mean accuracy of back calculated concentration of 
LQC and HQC samples prepared from different biological 
matrix lots should be within the range 85.00-115.00%.
Linearity
The linearity of the method was evaluated at eight 
concentration levels including the LLOQ. The calibration 
curve was found to be linear in the range 0.002–0.2 µg/
mL, with a correlation coefficient (r2) of 0.999. The 
calibration curves were defined in three runs based on 
triplicate assays of the spiked blank plasma samples. The 
linear graph is shown in Figure 2. Each back-calculated 
standard concentration was within the acceptance limits. 
The data of calculated calibration standards are presented 
in Table VI.
TABLE II - Auto sampler carryover
Sample ID
Peak Area % Carryover
Drug IS Drug IS
Unextracted samples
RS 0 0 N/A N/A
AQ ULOQ 65214 48695 0.00 0.00
RS 0 0
AQ LLOQ 945 48125 N/A N/A
Extracted samples
STD Blk 0 0 N/A N/A
ULOQ 47937 26914 0.00 0.00
STD Blk 0 0
LLOQ 457 26978 N/A N/A
TABLE III - Specificity and screening of biological matrix
Sample 
Response % Interference
Pass/Fail
Drug IS Drug IS
STD Blk1 0 0 0.00 0.00 Pass
LLOQ1 450 26359
STD Blk2 0 0 0.00 0.00 Pass
LLOQ2 498 26478
STD Blk3 0 0 0.00 0.00 Pass
LLOQ3 512 26921
STD Blk4 0 0 0.00 0.00 Pass
LLOQ4 465 25986
STD Blk5 0 0 0.00 0.00 Pass
LLOQ5 497 26519
STD Blk6 0 0 0.00 0.00 Pass
LLOQ6 491 26189
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Precision 
The inter-day and intraday precisions were 
measured as relative standard deviations and expressed 
as percentages of the concentration (Alanazi et al., 2012) 
of Axitinibe. The % CV of estimated concentrations for all 
four quality control samples with six replicates for analyte 
was within the range 6.54-11.68%. The % mean accuracy 
for LLOQ, LOQ, MOQ and HQC was within the range 
95.06-107.71%. For inter-day precision and accuracy, the 
% CV and accuracy results of all quality control samples 
were within the ranges 7.49-8.95% and 98.51-104.84%, 
respectively. The acceptance criterion states that at least 
67% of the QC samples should be ≤15.00% and for the 
LLOQ should be ≤20.00%. % Mean accuracy for LQC, 
MQC and HQC samples should be within the range 85.00-
TABLE V - Matrix effect
S. No. Plasma Lot No. HQC LQC
Nominal Concentration (µg/mL)
0.150 0.020
Nominal Concentration Range (µg/mL)
(0.128-0.173) (0.017-0.023)
Calculated Concentration (ng/mL) (n=3)
1 LOT1 0.137 0.019
2 LOT2 0.155 0.021
3 LOT3 0.170 0.021
4 LOT4 0.144 0.018
5 LOT5 0.162 0.022
6 LOT6 0.163 0.020
Mean 0.1551 0.0201
SD 0.01386 0.00160
% CV 8.94 7.98
% Mean Accuracy 103.41 100.56
No. of QC Failed 0 0
TABLE IV - Sensitivity data
Sample LLOQ
Nominal Concentration (µg/mL)
0.002
Calculated Concentration (µg/mL)
1 0.0021
2 0.0021
3 0.0020
4 0.0020
5 0.0023
6 0.0023
N 6
Mean 0.0021
 SD 0.00014
% CV 6.44
% Mean Accuracy 107.31 FIGURE 2 - Calibration plot for concentration v/s area ratio.
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115.00% and for the LLOQ sample should be within the 
range 80.00-120.00%. The data for precision and accuracy 
are given in Table VII. The chromatogram of quality 
control samples is shown in Figures 3-7. The data obtained 
indicate an acceptable precision for all concentrations 
assayed for both intraday and inter-day samples.
Recovery of analyte
Recovery is the detector response obtained from 
an amount of analyte added to and extracted from the 
biological matrix (FDA, 2001). The extraction recovery of 
axitinibe at HQC, MQC and LQC was found to be 50.45, 
TABLE VII - Precision interday and intraday data
HQC MQC LQC LLOQ 
Nominal Concentration (µg/mL)
0.150 0.080 0.020 0.002
Day 1 (n=6)
Mean 0.1582 0.0804 0.0196 0.0022
SD 0.01383 0.00849 0.00128 0.00016
%CV 8.75 10.56 6.54 7.59
% Mean Accuracy 105.44 100.54 98.08 107.71
Day-2 (n=6)
Mean 0.1550 0.0761 0.0202 0.0021
SD 0.01389 0.00610 0.00236 0.00014
%CV 8.96 8.02 11.68 6.80
% Mean Accuracy 103.30 95.06 101.04 105.33
Day-3 (n=6)
Mean 0.1587 0.0799 0.0210 0.0020
SD 0.00882 0.00678 0.00163 0.00022
%CV 5.56 8.48 7.76 11.05
% Mean Accuracy 105.78 99.93 105.04 101.45
Between Batch Precision and Accuracy 
N 18 18 18 18
Mean 0.1573 0.0788 0.0203 0.0021
SD 0.01178 0.00705 0.00180 0.00018
%CV 7.49 8.95 8.89 8.47
% Mean Accuracy 104.84 98.51 101.39 104.83
TABLE VI - Linearity
S. No. Conc. 
(µg/mL)
Back Calculated Concentration (µg/mL)
Avg. %CV % Mean Accuracy1 2 3
1 0.002 0.002 0.002 0.002 0.002 2.13 107.50
2 0.004 0.004 0.004 0.005 0.004 13.05 98.33
3 0.020 0.018 0.019 0.018 0.018 3.15 91.67
4 0.040 0.039 0.041 0.042 0.040 3.89 101.58
5 0.080 0.076 0.082 0.088 0.082 7.47 102.21
6 0.100 0.098 0.112 0.102 0.104 6.89 104.03
7 0.150 0.145 0.166 0.143 0.151 8.42 100.89
8 0.200 0.185 0.228 0.214 0.209 10.49 104.50
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57.40 and 58.21, respectively, and that of the internal 
standard was 74.76. This indicates that the results are 
coherent. The results of the recovery study are given in 
Tables VIII and IX. The results are within the acceptance 
limit. The acceptable limit was % CV of recovery at each 
QC level and IS of ≤15.00%. The overall mean recovery 
% CV for all QC levels should be ≤20.00%.
Ruggedness
The present method showed good ruggedness 
when it was performed using different analysts and on 
different instruments of the same make. The results of the 
ruggedness study for axitinibe were within the acceptance 
limit. The data are shown in Table X. The precision and 
accuracy values for different columns with different 
analysts ranged from 4.21% to 10.68% and 94.85% to 
110.60%.
Stability studies
The stability of the analytes was studied by keeping 
replicates of low, middle and high quality control samples 
at Zero hours, Long batch, LT at -28 °C and LT at -80 
°C. The results of LQC, MQC and HQC were found to 
be greater than 95%, which is within the acceptance 
limit. This shows that the analyte was stable for the 
entire analytical period. The results are compiled in 
Table XI.
SUMMARY AND CONCLUSION
The proposed HPLC method for the determination 
of axitinibe in rabbit plasma by using a UV detector is 
simple, accurate and utilizes protein precipitation with 
acetonitrile. The isocratic elution, short elution time of 
less than 10 min and UV detection makes the method cost 
effective. The results obtained prove that the method was 
FIGURE 7 - Chromatogram of ULOQ.
FIGURE 6 - Chromatogram of HQC.
FIGURE 5 - Chromatogram of MQC.
FIGURE 4 - Chromatogram of LQC.
FIGURE 3 - Chromatogram of LLOQ.
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TABLE X - Ruggedness data
P&A ID HQC MQC LQC LLOQ 
Nominal Concentration (µg/mL)
0.150 0.080 0.020 0.002
Nominal Concentration Range (µg/mL)
(0.128-0.173) (0.068-0.092) (0.017-0.023) (0.002-0.002)
Calculated Concentration (µg/mL)
Different Column
Mean (n=6) 0.1547 0.0784 0.0190 0.0022
SD 0.01651 0.00565 0.00134 0.00009
% CV 10.68 7.20 7.07 4.12
% Mean Accuracy 103.11 97.96 94.85 109.74
Different Analyst
Mean (n=6) 0.1528 0.0821 0.0205 0.0022
SD 0.00924 0.00619 0.00149 0.00010
% CV 6.05 7.55 7.25 4.50
% Mean Accuracy 101.89 102.61 102.60 110.60
TABLE IX - Recovery of internal standard
S. No. Unextracted Area Ratio Extracted Area Ratio
Mean (n=6) 35931.7 26755.2
SD 150.63 289.04
% CV 0.42 1.08
% Mean Recovery 74.46
TABLE VIII - Recovery of analyte
Sample HQC MQC LQC
Un extracted 
Response
Extracted 
Response
Un extracted 
Response
Extracted 
Response
Un extracted 
Response
Extracted 
Response
Mean (n=6) 70977.5 35805.3 42677.7 24495.7 1660.8 966.8
SD 812.76 254.91 545.80 192.05 31.61 16.71
% CV 1.15 0.71 1.28 0.78 1.90 1.73
% Mean 
Recovery
50.45 57.40 58.21
Overall % Mean 
Recovery
55.352
Overall SD 4.2685
Overall % CV 7.71
accurate and reproducible. In summary, the developed 
chromatographic method may be used for the routine 
bioanalysis of axitinibe.
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TABLE XI - Stability data
Sample Nominal Concentration (µg/mL)
Mean Calculated Concentration 
(µg/mL) ±SD. 
(n=6)
% CV
Stability on day zero 
HQC 0.150 0.1465±0.157 10.69
LQC 0.020 0.0196±0.002 8.05
Long batch at -28 °C
HQC 0.150 0.1536±0.014 8.91
LQC 0.020 0.0205±0.002 9.81
Long batch at -80 °C
HQC 0.150 0.1504±0.012 8.07
LQC 0.020 0.0189±0.001 7.29
Pharmaceutical Sciences, Gudlavalleru for providing 
facilities to carry out this work.
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